In Florida overlooking the Intercoastal Waterway..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMPG.. $0.021.. AmpliTech Receives Over $400,000 in New Orders
BOHEMIA, N.Y., March 3, 2015 (GLOBE NEWSWIRE) -- AmpliTech Group, Inc. (AMPG) announced today that it has received new orders valued at over $400,000 from international government and domestic private customers within the last 2 months. These new orders are for products for which AmpliTech has primarily been a sole source due to its unique and unparalleled performance attributes that have made AmpliTech the number one choice for our customers worldwide. These initial new orders are expected to position AmpliTech on long term supply chain roadmaps to provide its innovative and high performance products and solutions to mission critical programs.
CEO Fawad Maqbool stated, "AmpliTech's core product line is a perfect lead-in for the company in pursuit of its strategic objectives for large scale commercialization of its innovative technologies to drive the new product pipeline currently in the development for its newly formed Wireless Solutions Group. Clearly, what we are seeing is that the demand for our products is on the rise and is expected to substantially increase as we move forward with the transition into mass markets in line with our company strategy and vision as stated in previous press releases. We anticipate the increase in our bookings and backlog to continue throughout the remainder of the year as we move forward with our initiatives to shape the future of AmpliTech product offerings."
About AmpliTech Group, Inc.
AmpliTech Group, Inc. is an innovative provider of advanced radio frequency technology solutions serving applications from 50 kHz to 100 GHz across a diverse mix of markets. AmpliTech designs, develops, and manufactures custom and standard state-of-the-art RF and microwave and millimeter-wave components and integrated modules for the Domestic and International, SATCOM, Space, wireless infrastructure, test & measurement, and Military markets. In addition to our product offerings we leverage our design and product development expertise and core competencies to provide consulting and manufacturing services to our customers helping them reduce design cycle time and cost, achieve faster time to market, and lower manufacturing costs. Our steady growth over the past 13+ years has been the result of our commitment to not only meet, but to exceed the rigorous performance, quality, and reliability requirements of our diverse mix of customers. Click here to view AmpliTech video. Website: http://www.AmpliTechinc.com
Forward-looking Statements
This release contains statements that constitute forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
View photo
.
Contact:
Fawad Maqbool, CEO
AmpliTech Group, Inc.
(631) 521-7831
ACGX
I'm away and can't seem to get the volume to work on my phone.. Could someone PM me with the latest quote and volume.. thanx,, hank
As usual when it's quiet they are converting.. Has any one asked HOW MANY shares are now outstanding and auth. It's too soon for a run because the NEW PREFERRED still have a little time before they may be converted.. They unlike other converted shares have no restriction on percentage of ownership and carry a much larger discount than previously converted shares.. Also looking at who they were sold to will shed light on why this puppy is in a holding pattern until at least MAY...
KLYG..$0.09.. I'm happy that they stay dark because after speaking to the new PR guy the direction they are taking is best for shareholders... I added again today... READ THE LAST PR,, his name and tel. are on the bottom... Good luck.. hank
IFCR.. In a week you will look like a champ.. Once they find out what the fully diluted shares are they will realize that if they asked for their shares,, they would be worth more in scrap paper worth than share value..
BTW, It looks like failed P&D has just been done on CSNG .... Because it's a CHINA stock I'm always suspect but the numbers look somewhat real. ANY THOUGHTS FROM THE BOARD...
NGHT $0.0299... I have been looking at NGHT for some time and I think there is value there.. I'm not crazy about the share structure or the possibility of more shares outstanding but do believe the concept is viable and more important repeatable..
I am coming to the belief that if they present ,, those who like an fair type place to gather will come.. I also think that almost every large fair in the US could be a potential for their type of performing with acts already preforming for them BECAUSE A SHOW THAT THEY DON'T HAVE TO BOOK AND GET PAID FOR MAKES SENSE TO MOST COMMUNITY OPERATORS ,, WHO MOST ARE VOLUNTEERS.. Smaller fairs could also become a breeding ground for them to establish new talents..
It took me a while to get the concept but I think I've finally got..
NGHT follower's will make a mistake if they follow because of the results of just one outing and do not look at the total ..
As to the shares ,, I THINK GREED WILL TAKE OF THAT ONCE THE TOTAL COCEPT IS REALIZED.....
NGHT $0.029... I have been looking at NGHT for some time and I think there is value there.. I'm not crazy about the share structure or the possibility of more shares outstanding but do believe the concept is viable and more important repeatable..
I am coming to the belief that if they present ,, those who like an fair type place to gather will come.. I also think that almost every large fair in the US could be a potential for their type of performing with acts already preforming for them BECAUSE A SHOW THAT THEY DON'T HAVE TO BOOK AND GET PAID FOR MAKES SENSE TO MOST COMMUNITY OPERATORS ,, WHO MOST ARE VOLUNTEERS.. Smaller fairs could also become a breeding ground for them to establish new talents..
It took me a while to get the concept but I think I've finally got..
NGHT follower's will make a mistake if they follow because of the results of just one outing and do not look at the total ..
As to the shares ,, I THINK GREED WILL TAKE OF THAT ONCE THE TOTAL COCEPT IS REALIZED.....
NGHT $0.029... I have been looking at NGHT for some time and I think there is value there.. I'm not crazy about the share structure or the possibility of more shares outstanding but do believe the concept is viable and more important repeatable..
I am coming to the belief that if they present ,, those who like an fair type place to gather will come.. I also think that almost every large fair in the US could be a potential for their type of performing with acts already preforming for them BECAUSE A SHOW THAT THEY DON'T HAVE TO BOOK AND GET PAID FOR MAKES SENSE TO MOST COMMUNITY OPERATORS ,, WHO MOST ARE VOLUNTEERS.. Smaller fairs could also become a breeding ground for them to establish new talents..
It took me a while to get the concept but I think I've finally got..
NGHT follower's will make a mistake if they follow because of the results of just one outing and do not look at the total ..
As to the shares ,, I THINK GREED WILL TAKE OF THAT ONCE THE TOTAL COCEPT IS REALIZED.....
MNDO.. WASH AND RINSE..*Board Declares Cash Dividend
Yoqneam, Israel, February 26, 2015 MIND C.T.I. LTD. – (NasdaqGM:MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for service providers as well as unified communications analytics and call accounting solutions for enterprises, today announced results for the fourth quarter and year ended December 31, 2014.
The following will summarize our business in the fourth quarter of 2014 and provide a more detailed review of the financial results for the quarter. The financial results can be found in the Investors section www.mindcti.com/investor/PressReleases.asp and in our Form 6-K.
Financial Highlights of Q4 2014
· Revenues of close to $6.5 million, same as the third quarter of 2014, and up 28% from $5.1 million in the fourth quarter of 2013.
· Operating income was $2.5 million, up 15% sequentially from the third quarter of 2014 and compared to $1.0 million in the fourth quarter of 2013.
· Net income of $1.9 million or $0.10 per share, compared to $1.0 million or $0.05 per share in the fourth quarter of 2013.
· One modest win and multiple upgrades.
As of December 31, 2014 we had 352 employees, the same as of December 31, 2013.
Year 2014 Financial Highlights
· Revenues of $25 million, up 35% from $18.5 million in 2013.
· Operating income was $7.5 million, or 29.8% of revenue, compared to $2.2 million, or 11.7% of revenue, in 2013.
· Net income of $5.5 million, or $0.29 per share, compared to $2.2 million or $0.12 per share in 2013.
· Cash flow from operating activities was $3.8 million, compared to $5.2 million in 2013.
· Cash position of approximately $19.3 million as of December 31, 2014.
Monica Iancu, CEO, commented: “We are pleased that in 2014 we succeeded to translate the large deals we signed in 2013 into revenues through successful execution of the implementation of our projects milestones. While in 2014 we reached exceptional revenues and operating margins, some new deals that we expected to close in 2014 were delayed, thus our booking is lower than a year ago.”
Revenue Distribution for Q4 2014
Revenues in the Americas represented 54.5% of total revenues, revenues in Europe represented 34.2% and revenues in Israel represented 6.6% of total revenues.
Revenues from our customer care and billing software totaled $5.5 million, or 85% of total revenues, while revenues from our enterprise call accounting software were $1.0 million, or 15% of total revenues.
Revenues from licenses were $1.2 million, or 18% of total revenues, while revenues from maintenance and additional services were $5.3 million, or 82% of total revenues.
Revenue Distribution for Full Year 2014
Revenues in the Americas represented 57.6%, revenues in Europe represented 28.6% and revenues in Israel represented 9.0% of total revenue.
1
Revenues from our customer care and billing software totaled $21.0 million, or 84% of total revenues, compared with $14.2 million, or 77% of total revenues in 2013, while revenues from our enterprise call accounting software were $4.0 million, or 16% of total revenue, compared with $4.3 million or 23% of total revenues in 2013.
Revenues from licenses were $5.4 million, or 21.6% of total revenues, compared with $4.6 million, or 25% of total revenues in 2013 while revenues from maintenance and additional services were $19.6 million, or 78.4%, compared with $13.9 million or 75% of total revenues in 2013.
New Wins & Follow-on Orders in Q4 2014
In the fourth quarter we had one modest new win as well as some major upgrades from existing customers, the upgrades mainly for service enhancements and additional functionalities.
The new win is with a leading European global financial services company. PhonEX-ONE has been chosen for its advanced telecom business analysis and cost control management solution for global organizations.
One major upgrade includes enhancement of the MIND system to distinguish between data services (Internet, MMS, VoLTE), and to authorize and rate these differently. MIND will provide different configurable authorization amounts for “capping” the data services that will be offered by this customer.
Dividend Distribution
Since July 2003, when we first adopted a dividend policy, according to which we declare, subject to specific Board approval and applicable law, a dividend distribution once per year, we have distributed 11 yearly dividends with an average of 21 cents per share.
We continue to believe that our annual dividends enhance shareholders value and we plan to continue with yearly distributions.
Taking into consideration our dividend policy and the remaining cash after the distribution, our Board declared on February 26, 2015 a gross dividend of $0.30 per share. The record date for the dividend will be March 12, 2015 and the payment date will be March 26, 2015. Tax will be withheld at a rate of about 24%.
Investing in R&D
In order to maintain a state-of-the-art technology, each year we invest in R&D, sometimes adding new modules, sometimes in order to be compliant with new standards and many times to keep up with the new tools and new platforms that we use to build upon.
In 2014, along with supporting the additional needs defined by our customers, we invested significantly in a massive upgrade of the MINDBill infrastructure that includes technology updates of the entire spectrum, including application infrastructure, application server and database upgrades and improved monitoring.
New Office in Romania
Lately we started to analyze the option to open a new MIND office location in East Europe in order to enlarge and diversify our teams, mainly in the Professional Services department.
We checked the availability of qualified resources and office space in several locations, and we decided that Suceava, Romania is the preferred location. Our second location in Romania started to operate on February 16, 2015.
Monica concluded: “We are pleased as always with the growing recurring revenues and the follow-on orders that reconfirm our customer satisfaction. We operate in a very active market that shows continuous demand for our products and services and we expect that in 2015 we will be able to close new deals and significant follow-on orders. The valuable customer base, well supported by our devoted professional team and the ongoing investment in development of enhanced functionality and state-of-the-art technology are the basis for our expected long-term continuous performance.”
2
About MIND
MIND CTI Ltd. is a leading provider of convergent end-to-end billing and customer care product based solutions for service providers as well as unified communications analytics and call accounting solutions for enterprises. MIND provides a complete range of billing applications for any business model (license, managed service or complete outsourced billing service) for Wireless, Wireline, Cable, IP Services and Quad-play carriers in more than 40 countries around the world. A global company, with over thirteen years of experience in providing solutions to carriers and enterprises, MIND operates from offices in the United States, Romania and Israel.
Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995: All statements other than historical facts included in the foregoing press release regarding the Company's business strategy are "forward-looking statements." These statements are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements are not guarantees of future performance, and actual results may materially differ. The forward-looking statements involve risks, uncertainties, and assumptions, including the risks discussed in the Company's filings with the United States Securities Exchange Commission. The Company does not undertake to update any forward-looking information.
For more information please contact:
Andrea Dray
MIND CTI Ltd.
Tel: +972-4-993-6666
investor@mindcti.com
MNDO.. I too reloaded at the $3.35 level DURING THE PAST MONTH and did not sell a share yesterday.. Although the delayed orders spooked some I believe they are not lost and have become a source of easy comp. makers during this fiscal year.. MNDO IS MY 4'TH LARGEST POSITION.. HANK
Never thought of that,, is that like the groundhog seeing his own shadow again.. Or is it a new business for ACGX to be in.. They could sponsor a protein convention and get at least 5 PR's from it,.. But I think it's about time for another naked short release,, BECAUSE THAT LIKE IT'S FINANICALS CAN'T BE VERIFIED.. ONE THING THAT CONFUSES ME THE TERM BUDDY,, Are you finally getting it... Anyway I'm out of here for the rest of the week.. hank
YOU ARE SO RIGHT.. THE CONVERTERS HAVE REMOVED THIER SHARES BECAUSE THE CHARTS SHOW THAT ACGX IS RIPE FOR A BIG PUSH UPWARDS.. AT THIS LEVEL EACH YEAR IT'S TO THE MOON.. TIME TO LOAD UP AND WONDER IF IT'S WORKING AGAIN.. BUT THERE ARE NOW 27 TIMES MORE SHARES OUT THAN JUST TWO YEARS AGO.. THEY KNOW THAT WHEN IT MOVES IT IS EASIER TO DILUTE..
Sorry to correct anyone but there are less than 2.5 million shares on L2 to $1.00 so this real thin now..
BUT.. Someone just bought 15,500 shares to mark it back up.. Huge interest coming,, buy before they put out the next release.. Could be they are making a bid for another company in the paper processing area.. TOILET PAPER hangers so they will be able to supply them with their next big announcement.. Earnings will be down year over year just like the last qtr.. Has anyone looked at how much they spend on cars..
What really is needed now is another release now or better yet another e-mail posted from an insider giving reasons why they feel this stock is so oversold so they can flog newbe's with more stock from the converters... hank
WRONG BOARD..
ALQA $5.92..Interesting company added to the watch list.. Price at present is waaay to high for my taste but with all the news out at present lower prices could be ahead.. The current lows of the year could become an initial entry point..
Alliqua BioMedical, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
GlobeNewswire - Feb 24 07:30 EDT
Alert hits:*me EDG
Company Symbols: NASDAQ-SMALL:ALQA
Updates Fiscal 2015 Revenue Outlook
LANGHORNE, Pa., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
Q4 Highlights:
Total revenue increased 255% year-over-year to approximately $1.7 million. Organic revenue growth was 128% year-over-year.
Proprietary products revenue increased 1,170% year-over-year to approximately $1.3 million. Organic product revenue growth was 609% year-over-year.
On November 3rd, the Company announced Alliqua's Biovance® Human Amniotic Membrane Allograft has been assigned a new and unique, Level II Healthcare Common Procedure Coding System (HCPCS) product reimbursement Q code (Q4154) by the Centers for Medicare and Medicaid Services ("CMS"). This decision was a significant step towards obtaining comprehensive coverage reimbursement coverage for Biovance in the outpatient setting.
Highlights Subsequent to Quarter-End:
On January 5th, the Company announced a Group Purchasing Agreement with Premier, Inc.
On February 2nd, the Company announced a definitive agreement to acquire Celleration, Inc. for an initial purchase price of approximately $30.4 million, which is comprised of both cash and stock.
"Our fourth quarter operating and financial performance represents a strong end to fiscal year 2014 – an important year for Alliqua BioMedical," said David Johnson, Chief Executive Officer of Alliqua. "The profile of the Company changed dramatically in 2014, with growth in all areas of our organization – from leadership, to sales force and distribution infrastructure, to our portfolio of proprietary advanced wound care products - Alliqua BioMedical made significant progress towards our strategic objective of becoming a market-leading advanced wound care solutions provider."
"We expect continued progress in fiscal year 2015 and look forward to the continued growth in sales of our proprietary products – including our amniotic tissue membrane product Biovance – and the anticipated contributions in the second half of the year from our acquisition of Celleration which we announced earlier this month. We are pleased with our Company's notable progress in just a brief period of time, and we remain focused on continuing to execute our plan which we expect to drive revenue growth and market share gains, improving financial performance and above-average shareholder returns in 2015 and beyond."
Alliqua BioMedical, Inc. and Subsidiaries
Revenue Summary
($, Thousands) Three Months Ended December 31, Fiscal Year Ended December 31
2014 2013 2014 2013
Proprietary Products $1,349.0 $106.2 $3,003.5 $179.0
Contract Manufacturing 315.3 362.6 1,782.6 1,618.7
Revenue, net $1,664.3 $468.8 $4,786.1 $1,797.7
Fourth Quarter 2014 Results:
Total revenue for the fourth quarter of 2014 increased $1.2 million, or 255% year-over-year, to $1.7 million. Sales of the Company's proprietary products – including hydrogels, Sorbion, Biovance and Therabond – increased $1.2 million, or 1,170%, year-over-year. Fourth quarter 2014 revenue includes contributions from Choice Therapeutics, which we acquired in May 2014, of approximately $596 thousand. Excluding the contributions from the acquisition of Choice Therapeutics, the Company's proprietary products revenue increased in the fourth quarter 609%, year-over-year
Gross profit for the fourth quarter of 2014 increased $0.9 million year-over-year to $0.8 million, or 46.7% of sales. The increase in gross margin was driven by the change in product mix due to increased sales of proprietary products which represented 81% of sales in the fourth quarter of fiscal year 2014 compared to 23% of sales during the fourth quarter last year. Gross margin on proprietary product sales was 73% in the fourth quarter of 2014.
Total operating expenses for the fourth quarter of 2014 decreased approximately $7.2 million, or 54% year-over-year, to $6.1 million. Fourth quarter of 2013 total operating expenses included an impairment charge of $8.1 million related to in-process research and development for the Company's Hepamate technology. Excluding the impairment charge, adjusted operating expenses increased $0.9 million, or 18%, year-over-year. The increase in adjusted operating expenses in the fourth quarter of 2014 was driven primarily by higher compensation and benefits related to increased headcount compared to the prior year and the incremental expenses related to our acquisition of Choice Therapeutics. Stock-based compensation was $1.7 million and $2.6 million for the three months ended December 31, 2014 and 2013, respectively.
Loss from operations for the fourth quarter of 2014 was $5.3 million compared to a loss of $13.4 million last year. Net loss for the fourth quarter of 2014 was $5.4 million, compared to a net loss of $14.9 million for the same period last year.
Fiscal Year 2014 Results:
Total revenue for the twelve months ended December 31, 2014 increased $3.0 million, or 166% year-over-year, to $4.8 million. Sales of the Company's proprietary products – including hydrogels, Sorbion, Biovance and Therabond – increased $2.8 million, or 1,577%, year-over-year. Fiscal year 2014 revenue includes contributions from the acquisition of Choice Therapeutics in May 2014 of approximately $1.5 million. Excluding the contributions from the acquisition of Choice Therapeutics, the Company's proprietary products revenue increased 742%, year-over-year.
Gross profit for fiscal year 2014 increased $1.8 million to $1.5 million, or 31.7% of total sales, compared to a gross loss of $249 thousand last year. The increase in gross margin was due to a higher concentration of proprietary product sales. Product sales had a gross margin of 70% in fiscal year 2014. Net loss for the fiscal year of 2014 was $25.4 million compared to a net loss of $22.0 million for the same period last year.
As of December 31, 2014, the Company had $16.8 million in cash and cash equivalents, compared to $12.1 million at December 31, 2013. The increase was largely attributable to net financing proceeds of $14.4 million, proceeds from the exercise of stock options and warrants totaling $6.6 million offset by cash used in operating activities of $13.3 million and $2.0 million used for the purchase of Choice Therapeutics during the twelve months ended December 31, 2014.
Updated Fiscal Year 2015 Revenue Outlook
The Company is updating its revenue guidance for the fiscal year 2015 period. The updated guidance reflects the expected incremental contributions from the acquisition of Celleration, based on a closing date of June 30th.
For the fiscal-year ending December 31, 2015, the Company expects total revenue of $15.5 million to $18 million, representing growth at the mid-point of the range of approximately 250% year-over-year. This compares to the Company's previous expectation for total revenue in fiscal year 2015 in the range of $11 million to $13 million. Celleration revenue for the second-half of fiscal year 2015 is expected in the range of $4.5 million to $5.0 million. We expect sales from our contract manufacturing business to reflect slightly positive growth year-over-year, therefore, the growth rates reflected in the Company's revenue guidance for fiscal year 2015 are primarily generated by expected growth in the sale of the Company's proprietary products.
Conference Call
The Company will host a teleconference at 8:00 a.m. Eastern Time on February 24th to discuss the results of the quarter and fiscal year, and to host a question and answer session. Those interested in participating on the call may dial 888-576-4387 (719-457-2689 for international callers) and provide access code 6093126 approximately 10 minutes prior to the start time. A live webcast of the call will be made available on the investor relations section of the Company's website at http://ir.alliqua.com.
For those unable to participate, a replay of the call will be available for two weeks at 888-203-1112 (719-457-0820 for international callers); access code 6093126. The webcast will be archived on the investor relations section of Alliqua's website.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
ALQA $5.92..Interesting company added to the watch list.. Price at present is waaay to high for my taste but with all the news out at present lower prices could be ahead.. The current lows of the year could become an initial entry point..
Alliqua BioMedical, Inc. Reports Fourth Quarter and Fiscal Year 2014 Financial Results
GlobeNewswire - Feb 24 07:30 EDT
Alert hits:*me EDG
Company Symbols: NASDAQ-SMALL:ALQA
Updates Fiscal 2015 Revenue Outlook
LANGHORNE, Pa., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
Q4 Highlights:
Total revenue increased 255% year-over-year to approximately $1.7 million. Organic revenue growth was 128% year-over-year.
Proprietary products revenue increased 1,170% year-over-year to approximately $1.3 million. Organic product revenue growth was 609% year-over-year.
On November 3rd, the Company announced Alliqua's Biovance® Human Amniotic Membrane Allograft has been assigned a new and unique, Level II Healthcare Common Procedure Coding System (HCPCS) product reimbursement Q code (Q4154) by the Centers for Medicare and Medicaid Services ("CMS"). This decision was a significant step towards obtaining comprehensive coverage reimbursement coverage for Biovance in the outpatient setting.
Highlights Subsequent to Quarter-End:
On January 5th, the Company announced a Group Purchasing Agreement with Premier, Inc.
On February 2nd, the Company announced a definitive agreement to acquire Celleration, Inc. for an initial purchase price of approximately $30.4 million, which is comprised of both cash and stock.
"Our fourth quarter operating and financial performance represents a strong end to fiscal year 2014 – an important year for Alliqua BioMedical," said David Johnson, Chief Executive Officer of Alliqua. "The profile of the Company changed dramatically in 2014, with growth in all areas of our organization – from leadership, to sales force and distribution infrastructure, to our portfolio of proprietary advanced wound care products - Alliqua BioMedical made significant progress towards our strategic objective of becoming a market-leading advanced wound care solutions provider."
"We expect continued progress in fiscal year 2015 and look forward to the continued growth in sales of our proprietary products – including our amniotic tissue membrane product Biovance – and the anticipated contributions in the second half of the year from our acquisition of Celleration which we announced earlier this month. We are pleased with our Company's notable progress in just a brief period of time, and we remain focused on continuing to execute our plan which we expect to drive revenue growth and market share gains, improving financial performance and above-average shareholder returns in 2015 and beyond."
Alliqua BioMedical, Inc. and Subsidiaries
Revenue Summary
($, Thousands) Three Months Ended December 31, Fiscal Year Ended December 31
2014 2013 2014 2013
Proprietary Products $1,349.0 $106.2 $3,003.5 $179.0
Contract Manufacturing 315.3 362.6 1,782.6 1,618.7
Revenue, net $1,664.3 $468.8 $4,786.1 $1,797.7
Fourth Quarter 2014 Results:
Total revenue for the fourth quarter of 2014 increased $1.2 million, or 255% year-over-year, to $1.7 million. Sales of the Company's proprietary products – including hydrogels, Sorbion, Biovance and Therabond – increased $1.2 million, or 1,170%, year-over-year. Fourth quarter 2014 revenue includes contributions from Choice Therapeutics, which we acquired in May 2014, of approximately $596 thousand. Excluding the contributions from the acquisition of Choice Therapeutics, the Company's proprietary products revenue increased in the fourth quarter 609%, year-over-year
Gross profit for the fourth quarter of 2014 increased $0.9 million year-over-year to $0.8 million, or 46.7% of sales. The increase in gross margin was driven by the change in product mix due to increased sales of proprietary products which represented 81% of sales in the fourth quarter of fiscal year 2014 compared to 23% of sales during the fourth quarter last year. Gross margin on proprietary product sales was 73% in the fourth quarter of 2014.
Total operating expenses for the fourth quarter of 2014 decreased approximately $7.2 million, or 54% year-over-year, to $6.1 million. Fourth quarter of 2013 total operating expenses included an impairment charge of $8.1 million related to in-process research and development for the Company's Hepamate technology. Excluding the impairment charge, adjusted operating expenses increased $0.9 million, or 18%, year-over-year. The increase in adjusted operating expenses in the fourth quarter of 2014 was driven primarily by higher compensation and benefits related to increased headcount compared to the prior year and the incremental expenses related to our acquisition of Choice Therapeutics. Stock-based compensation was $1.7 million and $2.6 million for the three months ended December 31, 2014 and 2013, respectively.
Loss from operations for the fourth quarter of 2014 was $5.3 million compared to a loss of $13.4 million last year. Net loss for the fourth quarter of 2014 was $5.4 million, compared to a net loss of $14.9 million for the same period last year.
Fiscal Year 2014 Results:
Total revenue for the twelve months ended December 31, 2014 increased $3.0 million, or 166% year-over-year, to $4.8 million. Sales of the Company's proprietary products – including hydrogels, Sorbion, Biovance and Therabond – increased $2.8 million, or 1,577%, year-over-year. Fiscal year 2014 revenue includes contributions from the acquisition of Choice Therapeutics in May 2014 of approximately $1.5 million. Excluding the contributions from the acquisition of Choice Therapeutics, the Company's proprietary products revenue increased 742%, year-over-year.
Gross profit for fiscal year 2014 increased $1.8 million to $1.5 million, or 31.7% of total sales, compared to a gross loss of $249 thousand last year. The increase in gross margin was due to a higher concentration of proprietary product sales. Product sales had a gross margin of 70% in fiscal year 2014. Net loss for the fiscal year of 2014 was $25.4 million compared to a net loss of $22.0 million for the same period last year.
As of December 31, 2014, the Company had $16.8 million in cash and cash equivalents, compared to $12.1 million at December 31, 2013. The increase was largely attributable to net financing proceeds of $14.4 million, proceeds from the exercise of stock options and warrants totaling $6.6 million offset by cash used in operating activities of $13.3 million and $2.0 million used for the purchase of Choice Therapeutics during the twelve months ended December 31, 2014.
Updated Fiscal Year 2015 Revenue Outlook
The Company is updating its revenue guidance for the fiscal year 2015 period. The updated guidance reflects the expected incremental contributions from the acquisition of Celleration, based on a closing date of June 30th.
For the fiscal-year ending December 31, 2015, the Company expects total revenue of $15.5 million to $18 million, representing growth at the mid-point of the range of approximately 250% year-over-year. This compares to the Company's previous expectation for total revenue in fiscal year 2015 in the range of $11 million to $13 million. Celleration revenue for the second-half of fiscal year 2015 is expected in the range of $4.5 million to $5.0 million. We expect sales from our contract manufacturing business to reflect slightly positive growth year-over-year, therefore, the growth rates reflected in the Company's revenue guidance for fiscal year 2015 are primarily generated by expected growth in the sale of the Company's proprietary products.
Conference Call
The Company will host a teleconference at 8:00 a.m. Eastern Time on February 24th to discuss the results of the quarter and fiscal year, and to host a question and answer session. Those interested in participating on the call may dial 888-576-4387 (719-457-2689 for international callers) and provide access code 6093126 approximately 10 minutes prior to the start time. A live webcast of the call will be made available on the investor relations section of the Company's website at http://ir.alliqua.com.
For those unable to participate, a replay of the call will be available for two weeks at 888-203-1112 (719-457-0820 for international callers); access code 6093126. The webcast will be archived on the investor relations section of Alliqua's website.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Why would you even think anything is new..
A long but interesting article,everyone should read this. Might help,understand what is happening. "The Dirty Rotten Secrets of the Small Cap Markets" were previously unwritten rules, passed along verbally among stock promoters, company insiders, stock brokerage firm principals and many who are close to the outer fringes of this very exclusive club. Amazingly, many US and Canadian securities regulators have also been members of this very closed group. It is always interesting to discover how the head of a stock exchange's surveillance department, upon retirement from "public service," ends up as a senior vice president at the brokerage house with which he once squabbled or, vice versa, the favorite son of a brokerage firm later becomes the head of a securities commission. The financial markets are truly a revolving door, whereby this year's company insider was once a stockbroker; whereby a highly aggressive SEC attorney pursuing a scandalous media personality "suddenly" retires and becomes a senior executive at the Smith Barney brokerage firm. One thing is for certain, in the apparently uncertain world of "the business," YOU are on the outside looking in. The stock market is rigged against you and in ways you may never discover. The rules, laws, secrets and axioms I've listed in this essay should give you a much clearer understanding about the inner workings of the financial marketplace. No one has previously codified the "omerta," or code of silence which is rampant throughout the financial markets. One would become a pariah, an undesirable or an outcast, by writing these down and broadly disseminating them. You are NOT supposed to know these unwritten rules and God help the individual who passes them onto you.
The Dirty Rotten Secrets of the Small Cap Markets
1. LAW OF THE PEZ. This is dedicated to Murray Pezim, once the most powerful stock promoter in all of Canada. According to legend, Mr. Pezim, upon hearing that someone had made a killing on his stock play, immediately remarked, "Shareholder profits are short-term loans." Ultimately, if you continue your small-cap speculations, you will lose. Either the markets will turn or you will drop your guard, but eventually, you will lose. One should understand that the small cap stock markets run pretty much like a casino.... the longer you stay at the tables, the greater your chances of failure.
2. MOTTO OF THE STOCK PROMOTER. Sell when everyone is buying and buy when everyone else is selling. Actually, more often it is, sell when everyone else is buying, completely exit the play, and go find something else for them to buy later. It may even be: Start shorting your deal when you've sold out your entire position so you can score even more profit on the way down. There are corollaries to this motto, such as "never get married to a deal," or "never believe in your own deal," or "have a new deal ready to rock & roll as soon as the current one flops."
3. LAW OF THE UPTICKS. Stocks that are running higher are said to be upticking. Despite every effort I have made to emphasize that the best time to buy a stock is when it is low and boasts a sorry-looking flatline stock chart, speculators inevitably chase stocks to new highs. Stock promoters and insiders buy, or obtain a position, at the low and sell during the promotion or "discovery." Sadly, there will always be some type of promotion that will create upticks and speculators will chase that stock to a new level. Greed generates upticks. What stock promoters know that you don't is this law: A herd of speculators will only buy on the UPTICK.
4. AXIOM OF GREED. In an earlier essay, I isolated that greed originated from a "perceived" lack of speculative opportunities. This false perception causes a speculator to get greedy and chase a stock to a new level. If one has a hundred speculative opportunities on their plate, one is less eager to chase any specific stock. The lesser the number of opportunities one reviews, the greedier one becomes to chase a heavily promoted stock. A stock promoter will, thus, make "his stock" appear to look like the only game in town worth playing. Greed essentially emanates from deprivation.
5. RULE OF CONFUSION. The only time one rushes into a quick decision is when they are confused or disoriented or misled. The stock promoter's greatest weapon is CONFUSION: Catch a speculator off guard and sucker him into a stock. The more disoriented or confused the speculator, the greater his chances of being snared. Stock promotions include an overwhelming amount of data, reports, corporate reviews and so forth that are packaged in such a way as to confuse the speculator. If, at any time, you are overwhelmed with out-of-control emotions or data which you don't understand, it is better to stay out of the play.
6. SECRET OF EXCITEMENT. You've heard about the "forbidden fruit" or "unknown pleasures." As long as something remains a mystery, it can create an "excitement." Excitement is a sensation which one commonly associates with pleasure. Therefore, when an exciting proposition is offered, you may readily accept it in order to experience THAT sensation. When someone heaps excitement after excitement, upon you, in either the written or spoken word and/or with graphics (visuals, photographs, charts, drawings, etc.) and especially in a loud or emphatic manner, you become disoriented and confused. One overcomes this "sensation of the unknown or forbidden" through experience, often with a rude and unpleasant awakening. Stock promoters abuse your inexperience, and naiveté, to sell you stock. ALL mining speculations are exciting until the assays come back or a mine goes into development. Then reality sets in.
7. LAW OF WAITING. The longer you wait, the greater your chances for failure. This applies to both holding a stock which is declining and to a stock which is running. The odds are greater than 90% against you... that you will fail in a speculation, if you wait for it to recover or if you chase a stock which has already begun its run. Generally, a stock moves up in less than two weeks, often in two to five days. The waiting period, for a stock to allegedly recover, is the slow, dragged out retreat you later observe in the share price. As believers stop believing, the share price declines, often never recovering. Of course, if one wants to wait forever, then eventually the stock may recover. The longer one waits, during a runup, the smaller one's potential profits and the greater one's exposure to losses. (One important caveat: Occasionally, there are a few good deals--about 20 or 30 annually--when one SHOULD wait for the company to mature. Almost always, they come out of left field and, rarely, does anyone know in advance which company will become tomorrow's success story.)
8. AXIOM OF BELIEVING. The higher your expectations in a stock, the greater your chances of losing money in that speculation. All of the promotion is geared to make you a "believer." Most speculators are betting on a tip or a rumor. They are taking someone else's "word" for the outcome. Absolutely no one should invest or speculate in a stock without understanding the risks as well as the reward. Stock promoters create believers by providing ONLY the reward potential, without also including the risk factors. Believers eventually discover the risks, long after the stock has begun its decline.
9. LAW OF LOSERS. Oddly, those most attracted to speculative markets are failures in other aspects of their lives. They may be wealthy, but consider themselves, in some way, as having "failed." Medical doctors are prime targets of stock promoters, as they are not only affluent may have "settled for less" in their lives or feel they "are owed more" for the work they do. Whoever has failed, in some key aspect of their life, often tries to make up for it by gambling....often speculating in these markets. The loser is always trying to compensate for a failure in another part of his life and continues to heavily lose as a speculator. (Note: I stay in touch with certain losers and use them as a yardstick for my trading -- when they buy, I sell; when they sell, I buy. The loser has a knack for exiting his position, a day or a week before a major runup; or he/she simply always buys at the top of the runup. The downside to communicating with losers is that they are so darned indecisive and fretters; their worrying can and does rub off and creates a confusion for oneself.)
10. LAW OF THE SUCKER. PT Barnum was right: A sucker is born every minute. For every speculator that is wiped out, a fresh one is champing at the bit to start betting. Stock promoters prop up their plays by finding new blood to drain. The greener the speculator, the redder the carpet laid out for him. If there were no new suckers coming into the game, it would all be over.
11. SECRET OF THE AREA PLAY. Virtually all area plays fail. Rarely is there a long-term beneficiary to that area play, other than the initial company which made the discovery. The secret of the area play depends upon #1 (Law of the Pez). Those who profited from the share price runup of the company making the discovery are then offered a "second chance" or a third or a fourth with the rush of new companies into that area. Primarily, these companies are trying to finance other explorations elsewhere, but the fact that they staked some ground or bought some cheap claims doesn't stop them from parlaying that into an artificially inflated market capitalization. Inevitably, 99% of these companies fail to deliver, which is soon reflected in their vaporized share prices. Stock promoters, knowing well their chances of success were always very slim at best, long ago dumped their shares. The last one into the area play tends to have the worst chances of success.
12. THE GURU AXIOM. The least profitable time to follow any guru (stock promoter, newsletter writer, company insider) is immediately following his last successful play. The cliché that "he is only as good as his last play" is a promotional device effectively utilized to attract new money into a new play. If one looks at some of Canada's recent success stories in the mining business, the BEST time to follow the guru is immediately after his or her failure. Those who "had it," failed miserably and later bounced back seem to offer the highest probability of success. Often, there is a rush of money into the guru's "new play," which quickly exits when they discover that "this ain't the same one as the last one." It never is. Of course, every guru is keen on pointing out all of his previously successful plays and forgets about his failures. Self-fulfilling prophesies require substance in order to survive. Catch the "gurus" when they are down and out and heed their advice at that point in their careers. You may increase your chances of success. Hint: Sheer desperation drives them to repeat their success or to completely leave the business.
13. CANADA'S BEST KEPT SECRET. Many Canadian speculators don't pay for their stock. These Canadian speculators bet on stocks, against the equity in their account. We've heard about T-3, etc. That is bull. The truth is often, more like T-12 or T-20 (as in 12 or 20 days to settle instead of the required three days). Brokerage firms have been known to extend, to their best clients, the time they can hold "unpaid stock" for weeks. What is also not very well known is that brokerage firms can, and frequently do, short sell any stock which remains unpaid (they do so to protect themselves). Thus, during an exciting runup, one observes (or hears about) massive shortselling of a stock -- the stock wasn't paid for, so the brokerage firm shorts it. A brokerage firm's credit manager can quite excitedly extend your "credit terms" so that you have "more time to pay for your stock." Essentially, you end up betting against yourself, under these circumstances, because the brokerage firm is shorting your purchase. Later, you end up selling at a loss and the brokerage firm covers at a profit. The house nearly always wins. Your stockbroker gets his commission whether you lose or not.
14. THE CANADIAN LAW OF SHORT SELLING. While it is very expensive and deadly for the unsophisticated speculator to short a Canadian stock, brokerage firms can easily short stocks. They short against their "inventory." Generally, any rush of excitement into a stock is done under a short, speculative time frame (whereupon the speculator doesn't actually pay for his stock). Brokerage firms short sell against the unpaid speculation and drive the stock price down, down, down. As very large Canadian brokerage firms also accept many US stock orders, they short sell virtually every order which arrives. While the US investor pays for his/her stock, the Canadian firm can short sell against it, because rarely is delivery ever taken on that stock. As long as the certificates remain in the brokerage firm, it can be shorted.
15. AXIOM OF MOTION. What emotionally upsets any speculator is a LACK of motion. It is the absence of motion which prevents a speculator from patiently accumulating shares in a flatline stock (the share price remains constant at, or near, the floor of its stock chart). Speculators are eager to make their money work for them. Thus, if a stock doesn't move, they panic. Gradual downward motion rarely creates a panic. Imagine yourself in a well-lit room with a dimmer light. Stock promoters gradually turn down the lights until you finally discover you are sitting in the dark. Conversely, when they want to create the excitement, they abruptly turn on the lights. A stock forever trading at the same price creates an emotional upset, thus the gradual "up and down" motion manufactured by stock promoters and insiders and brokers. "Get it to move" is their motto if they want you to hold your position. UP offers hope and a recovery of your initial investment or (finally!) a profit after having waited so long. DOWN drives fear up your spine and you remain fixated in the stock, like a deer in a car's headlights.
16. SECRET OF PANIC. If you hold a position in a stock and are panicking, you should not be holding that stock position. You probably don't know enough about the company or have mentally spent that money for some other purpose than speculating in that stock. You are also very low on the food chain of information. A stock promoter's investor relations department primarily exists to minimize, reduce or eliminate the panic you feel in obtaining and holding your stock position. Panic is manufactured in approximately the same way excitement is created. The secret to overcoming panic is this: When it all looks like the end of the world, that may be the best time to buy; when it all looks like the world is made of cream cheese, run for the exit doors. Please realize that, generally, if someone has created a panic within you, it is for some ulterior motive -- they are aggressively trying to get you to do the opposite of what you should be doing.
17. LAW OF STOCK OPTIONS. Insiders like to hold free stock, just like anyone. Stock options exist so that insiders and promoters can cause runups, thus selling off their stock and subsequently issuing new stock options. This law reads as follows: The ONLY reason stocks are runup is because of incentive stock options. If stock options didn't exist, we wouldn't see any stock runups. Because most small cap companies are broke, they pay promoters with stock options. Thus, the promoter has a vested interest to get a company's share price above a particular level.
18. AXIOM OF HISTORY. Leopards almost never change their spots. The same guy running a shoddy stock promotion, a few years ago, is going to run a similar disaster again. It behooves every speculator to dig deep and find out who are the characters in this current play. Many times, the dishonest stock promoter runs the play from a background cover using a front man. You will find them, by looking for their associates. Crooks run in the same circles. Occasionally, you can be thrown off by a new name. He has a history. Find out what it is before speculating. No matter the cost, it is a lot cheaper than the losses you may incur in your speculation.
19. LAW OF PAPER. Share certificates are like corpses until a stock promoter gives them life. All paper is intrinsically worthless unless there is someone who wants to pay you, to take the stock off your hands. If there were no promoters in this world, then you would never be able to exit your position.
20. RULE OF THE EQUIPMENT. The speculator who has the most sophisticated quotation equipment, knows how to use this equipment, understands the quotes and what they represent, effectively uses his equipment, and also the fastest phone line to the trader, gets in and out of his paper the fastest.
21. LAW OF THE INSIDER. The speculator who actually knows what the insider is doing, whether it is accumulating or dumping his position, will be the most successful speculator. Everyone else is guessing and will have a greater or lesser degree of failure in his speculation.
22. THE SPOUSE FACTOR. This could also be a corollary to Murphy's Law for a deal. The wife wants a new house, a new car, etc. And the promoter or insider sells, sells, sells to afford these new toys. Down goes the stock price.
23. AXIOM OF THE BID. A new wave of buying into any stock is a method for an insider, promoter or disgruntled shareholder to exit the position. One should look at "the bid" as the key which unlocks the door and permits one to exit a stock position. Conversely, one may wish to consider "the offer" as the trapdoor which could send a speculator to the bowels of hell.
24. LAW OF THE HOLY ROLLER. Jesus threw the moneylenders out of the temple. Anyone running his play under the guise of Jesus would anger the Almighty and bring ruin to his shareholders. I guess the only reason a promoter might turn to religion is that no one except God will forgive him for what he has done to his fellow man.
25. THE LAW OF WASH TRADING. Insiders, stockbrokers and marketmakers "fabricate" trading volume by trading shares among each other, in order to deceive investors into thinking that the stock is liquid. In the hands of a madman, of which there are many, wash trading becomes an artistic manufacturing of massive trading in the stock. A promoter or insider (market manipulator) can set up three to twenty brokerage accounts and cleverly trade the stock, up and down the charts. As soon as "new blood" comes into the stock, suckered in by a quick runup, down comes the stock as the market manipulator dumps and shorts his own stock. In one recent case, the intricacy of one promoter's trading got so complex that he relied on computerized buy/sell signals so he, himself, didn't lose his shirt.
26. AXIOM OF FREE STOCK. Everyone would love to get free stock. Clever speculators, insiders and stock promoters are generally those that actually DO get free stock. Insiders simply blow out all of their paper into the strength of any liquidity and then re-load with stock options and/or warrants, maintaining their stranglehold on the company while lining their pockets. Stock promoters secretly demand under-the-table share certificates, channeled usually through an "independent" third party into a hidden account. Successful speculators monitor stock charts, buying low and selling most (or half or all) of their position, wait for the stock to retreat, and then re-load. There's no free lunch in this business. All of the above takes work. IF all speculators/investors knew this, there would probably be less market manipulation, or at the very least, market manipulators would have to come up with a new bag of tricks.
27. LAW OF NAME-DROPPING. In an effort to strengthen bidding in a stock, promoters and insiders may claim a BIG name is getting behind the company, i.e. a famous (wealthy) individual is buying the stock (lots of it), a big-time promoter is getting behind the stock, a highly regarded analyst will recommend the stock, or a well-known newsletter writer will bring his subscribers into the stock. It's all just "noise," generated by the promoters so they can prop up their share price and offload their on paper. This law is a variation of the next law.
28. LAW OF THE TAKEOVER. If you hear there is going to be a takeover, someone is offloading their position in that company and anticipates doing so at a higher price. Takeovers are done quietly and carefully so that the conquering company doesn't have to overpay for their shares.
29. AXIOM OF THE LEAK (RUMOR). Any rumor is manufactured by an insider or stock promoter in order to dump their position onto the gullible. Unless one is a prankster.
30. LAW OF THE MEDIA. The Media are the last to know about anything. No one in their right mind trusts or likes the media. The media, in order to appease the regulators, only report bad news and routinely challenge or distrust good news and put a "bad news spin" on good news. Further, the media distrust anyone who makes more money than they do, especially the guy who owns the newspaper.
31. SECRET OF INVESTMENT CONFERENCES. These occur at a hotel or convention center where insiders and promoters exhibit their wares and praise their company's future in order to dump part or all of their stock position onto investors, stockbrokers and money managers who don't know any better.
32. AXIOM OF MOTIVATION. When properly motivated, stock promoters can create "miracles", if only temporary in the share price appreciation. Generally, the greater the payoff, the more liquid the trading volume. Signs to look for include lucrative investor relations contracts and/or plenty of stock promoters all touting the stock to their groups. Nothing replaces the best motivation of all, for the insider, like private placement paper becoming free trading.
33. SECRET TO QUICK MONEY. The quicker you try to make your money, the faster you lose it. Quick money is usually made dishonestly (drug dealing, racketeering, insider trading, etc.) or in a lottery. Nothing replaces burning the midnight oil, long hours of toiling, effective data gathering and data analysis and bright ideas. Many try using short-cuts, which ultimately become dead ends.
34. THE TRUTH ABOUT MOTHERS. Everything your mother ever told you about life, applies to the stock markets. Everything parents told their daughters about boys also applies to stock promoters.
35. LAW OF ORPHANS. No one is willing to own up or take responsibility for a disastrous crash in a stock or a failed stock promotion. Whenever there is a major success story, everyone takes credit for that company's success. The further you are out of the loop, the harder it will be for you to determine who was responsible for a company's success or failure.
36. FLAVOR-OF-THE-MONTH AXIOM. No individual ever survives as a Flavor of the Month. One can have an enviable string of successes, but eventually the insiders, shortsellers or stock promoters will destroy him. Failing that, the media will ruin him. Failing that, the regulators will handcuff and gag him, or even jail him. No one has ever survived past all of those roadblocks. Each roadblock wears the superstar down to the point, where he can no longer think straight and wonders if "all of this is worth doing anyway." Flavors-of-the month, like ice cream, eventually melt down to a dribble.
37. THE SECRET OF THE NEWSLETTER WRITER. Any newsletter writer providing ongoing reportage on Canadian mining or small cap stocks has a vested interest, whether disclosed or not. Someone is paying the freight and rarely is it the subscriber. (The writer either has a position or is being paid or hopes to become "famous" by covering a specific stock.) Publishing a newsletter is a very expensive proposition, with a high casualty rate. Look at which "popular" newsletters were published during the late 1960s or the early 1980s and see if any are still being published today.
38. AXIOM OF SECRETS. If there really is going to be a big discovery or a big contract or a big deal, the stock promoter or insider will never tell you first, if at all, until the news is made public. He knows it would be illegal to give you inside information so he won't. Whatever he does tell you may have no bearing in reality.The more desperate the promoter, the more outrageous the promises; the more incredible the deal.
39. THE SECRET TO HOWE STREET. All any of these stock promoters want to buy with the profits they make off you is this: Respectability. Instead, they buy drugs and booze. They utterly lack any self-respect, from the best to the worst. They are criminals who have whistled past the graveyard, more times than a cat with nine lives, praying that they can avoid being caught. At the very best, they hope to parlay their worthless share certificates, through a somewhat credible promotion, into bigger real estate and cash. At their worst, they merely wish to cover their annual bar tab. The average person, whom they routinely fleece, has far more self-respect than any of these promoters will ever achieve. None of them will ever become respectable, especially not in their own minds. This absence of self-respect may help explain the rampant alcoholism and drug abuse among stock promoters in Vancouver.
40. THE LAW OF MONEY. History shows us that Money is attracted to the individual who can effectively and articulately communicate. Stock promoters routinely can repeat a good story. The most successful speculators are those whose communications skills match or surpass the best promoters. The best CEO is the most effective communicator.
41. AXIOM OF TECHNICAL ANALYSIS . Technical analysis does not deceive the speculator. A stock promoter's worst enemy is the stock chart. Correctly interpreted stock charts never lie, although many speculators have no clue as to how to read a stock chart. Analysis may also vary from chartist to chartist.
42. THE HYPE FACTOR . Hyperbolic statements can artificially inflate a stock's price, temporarily. Long enough for a shortselling syndicate or a group of professional traders and insiders to reap huge rewards. Often, a combination of a speculator's naiveté and his enthusiasm about a company can lead to "over the top" statements. Eventually, he learns his lesson. Stock promoters favor newsletter writers who are inexperienced in the business, as they can be told what to write and are eager to be offered that opportunity.
43. THE LAW OF SEASONS. When it comes to mining plays, buy in December and sell in May. Buy when the promoters are out of town; sell when they are in full swing.
44. AXIOM OF DRILL RESULTS. Buy when the drill goes down; sell when the shaft comes up. In other words, the heady promotional statements and expectations are issued during the drill campaign and while awaiting assays. That is when a speculator most likely benefits from a stock's runup. Because most drill results are disappointing, the smart speculator is completely out of his position before the assays are announced.
45. THE LAW OF NEWS RELEASES. Buy on mystery, sell on history. Buy on rumor, sell on the news. These are well-worn clichés that rarely disappoint. Occasionally, a company's stock will run strongly after a news release. In the small cap stock sector, most news releases are a promotional device, used by insiders, to generate fantastic trading volume so they can exit a portion of their position.
46. THE SUCCESS FACTOR. Most mining success stories are complete accidents. On the order of a "Jed Clampett" finding oil in the TV series, "The Beverly Hillbillies." With many important discoveries, throughout the history of mining plays, one or many insiders had virtually blown out of their entire position and/or were shorting their own stock, in anticipation the company's drill results would be a disappointment. Part of the stock's runup might also have included covering their shortselling and obtaining a fresh, new position.
47. AXIOM OF NOISE . The more noise you hear during a stock promotion, the harder the stock will fall when the promotion is completed. Stock promoters are only interested in trading volume, for share-dumping purposes, which can only be created with a series of loud bangs in the media world. Generally, by the time you hear about the stock, the runup is over and the distribution phase has already started, followed by a slow or abrupt decline in the share price.
48. THE LAW OF LIARS. They repeat their lies and falsehoods again and again and again. They don't just tell one white lie and feel guilty. They lie in every aspect of their life. One can use this against the liar by doing the exact opposite of what he tells you to do. Liars are suckers for other liars.
49. AXIOM OF TRADING VOLUME. Trading volume is increased solely to distribute a large position from a single shareholder, or a few shareholders, to the masses. All an insider ever wants is trading volume so he has enough liquidity into which to dump his position. This is the only reason stock promoters are hired.
50. THE ULTIMATE RULE. Paper is paper and cash is cash. The only reason you are holding paper instead of cash is you honestly believe your paper will eventually be worth more than the cash. Amateurs buy paper. Professionals convert their paper to cash. Cash is King. Paper is essentially worthless if there are no buyers.
Conclusion...
This essay was not intended, but may serve, as a sociological study of the criminal minds at work within the financial marketplace. Speculators also have to agree to be criminals, to a degree, in that they expect something for nothing. The essence of the criminal is to get something for nothing. While theft, larceny, insurance fraud and burglary are broadly condemned within this society, it appears perfectly "all right" for the speculator to swoop into and out of a stock, for a quick profit. That is pickpocketing, plain and simple, and should be branded as such. Thus, it is no great surprise, to me, that an increasing number of the Internet "gurus" have told me they'd like to launch their own deal, i.e. to become an insider or stock promoter, themselves. It is a quick slide into the loony bin for anyone aggressively speculating in these markets.
The entire problem of the small cap stock market is the illegal transfer of wealth from the naive investor to the sophisticated trader. Institutional fraud runs uncontrolled throughout the fabric of these markets. Bribing stockbrokers appears to be the "only way to do business" in many circles. Bribing fund managers is nearly mandatory if a mining company wants European financing. What amazes me is that October's FBI sting of insiders and stock promoters wasn't even the tip of the tip of the iceberg -- they didn't even scratch the surface, nor did they nab the key figures. For all the hoopla and the celebration of the regulators over the recent successes in "stopping fraud," they all know, too well, that hardly a dent occurred. The actual depth of the amount of stock fraud, outright deception, bribery and dishonesty in the financial markets is far greater than any securities regulatory body is willing to admit. They know about the fraud -- but then, they have "their future" to look out for, as well. There's a job at Merrill Lynch, Charles Schwab, Canaccord or Smith Barney waiting for them. It's OK to "get the little guy," but they know better than to tangle with the powers that be, which run the financial markets from New York to Tokyo, from London to Vancouver, and everywhere in between.
Essentially, the securities regulators hold their esteemed positions, and are backed by their respective state/provincial/federal governments, for no other reason than to ensure that the small investor CONTINUES to get screwed every which way but Sunday. For if all the small investors always made a profit in their investments or speculations, the poor professionals wouldn't be able to steal as handsomely as they do now. This may also explain why marketmakers continue to FREELY rape small companies, while the regulators focus their attention on the stock promoters and insiders.n small caps.
wade.. if the market goes down 90 percent why do you think small stocks will do well..
this must be a joke.. 5.00 compensation..
DISCLOSURE OF COMPENSATION PAID TO HOOKA (15 U.S.C. Sec. 77q(b))
February 2015
GATA, $5.00 in cash compensation paid by a non controlling third party promoter
DRMC, $200.00 in cash compensation paid by a non controlling third party promoter
UBIQ, $200.00 in cash compensation paid by a non controlling third party promoter
ISCO, $200.00 in cash compensation paid by a non controlling third party promoter
STOY, $1800.00 in cash compensation paid by a non controlling third party promoter
GBHL, $5.00 in cash compensation paid by a non controlling third party promoter
EPAZ, $75.00 in cash compensation paid by promoter, StockGoodies, LLC
UTMR, $200.00 in cash compensation paid by a non controlling third party promoter
PZOO, $10.00 in cash compensation paid by a non controlling third party promoter
RNWEY.. $O.1028 BID.. earnings.. $0.05 EARNINGS NOW BACK TO BACK FOR THE 4'TH QTR..Listed on the Oslo Stock
Exchange (ticker: REC), the company is headquartered in Moses Lake, Washington
and employs 720 people.
Fornebu, February 13, 2015: REC Silicon ASA reported fourth quarter 2014
revenues of USD 126.2 million compared to USD 126.5 million in the third
quarter. Higher polysilicon sales volumes were offset by lower polysilicon
prices and decreased sales volumes of silicon gases.
EBITDA for the fourth quarter was USD 38.0 million. Third quarter EBITDA
included the recognition of USD 101 million associated with the transfer of
technology to the Yulin JV. The underlying comparable EBITDA decreased by
approximately 17 percent compared to the prior quarter, primarily due to lower
polysilicon prices.
The polysilicon and silane gas loading expansion projects at Moses Lake and
Butte are proceeding according to schedule. Building permits have been obtained
and construction activity has commenced. The Yulin Joint Venture is also
progressing according to plan. The contract on detailed engineering has been
awarded and the work has commenced. REC Silicon made the first capital
contribution of USD 75 million to the JV in October 2014.
"Continued focus on efficient and stable operations resulted in record high
production volumes and secured REC Silicon's competitive cost position.
Although challenging market dynamics and the uncertainty created by the US/China
trade dispute led to pressure on solar grade polysilicon prices during the
quarter, REC Silicon's financials remain strong," commented Tore Torvund, CEO of
REC Silicon.
Net financial items resulted in income of USD 112.8 million, mainly reflecting
net currency gains, and fair value adjustment of convertible bonds offset by
interest expense.
Profit from continuing operations was USD 119.0 million in the fourth quarter,
compared to USD 119.5 million in the previous quarter.
Basic and diluted EPS from total operations was USD 0.05 in the fourth quarter
2014, unchanged from the previous quarter.
For more information, please see the attached fourth quarter 2014 report.
Morning program:
The Company will give a presentation at 08:00 a.m. CET today at
Konferansesenteret Høyres Hus, Stortingsgaten 20, 0117 Oslo, Norway. The
presentation will be held in English.
There will be a live webcast from the presentation which can be accessed from:
www.recsilicon.com.
It will also be possible to listen to the presentation through a conference
call. Please make sure to dial in 10 minutes prior to scheduled start time on
one of the following numbers:
Norway: +47 23 50 04 86
UK: +44 (0)20 3427 1909
USA: +1 212 444 0412
International Toll: +44 (0)20 3427 1909
Please provide confirmation code 7022732 and state your name, company and
country of residence.
Afternoon program:
REC Silicon will host an analyst conference call with possibilities for
questions and answers later the same day at 3:00 p.m. CET. Please make sure to
dial in at least five minutes ahead of time to complete your registration.
International dial in: +47 23 50 04 86
Please provide confirmation code 1521035 and state your name, company and
country of residence.
For further information, please contact:
Mitra H. Negård, Investor Relations
REC Silicon ASA
Phone: +47 957 93 631
Email: mitra.negard@recsilicon.com
About REC Silicon
REC Silicon is a leading producer of advanced silicon materials, delivering
high-purity polysilicon and silicon gas to the solar and electronics industries
worldwide. We combine 25 years of experience and proprietary technology with the
needs of our customers, and annual production capacity of more than 20,000 MT of
polysilicon from our two US-based manufacturing plants. Listed on the Oslo Stock
Exchange (ticker: REC), the company is headquartered in Moses Lake, Washington
and employs 720 people.
For more information: www.recsilicon.com
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
RNWEY.. $O.1028 BID.. earnings.. $0.05 EARNINGS NOW BACK TO BACK FOR THE 4'TH QTR..Listed on the Oslo Stock
Exchange (ticker: REC), the company is headquartered in Moses Lake, Washington
and employs 720 people.
Fornebu, February 13, 2015: REC Silicon ASA reported fourth quarter 2014
revenues of USD 126.2 million compared to USD 126.5 million in the third
quarter. Higher polysilicon sales volumes were offset by lower polysilicon
prices and decreased sales volumes of silicon gases.
EBITDA for the fourth quarter was USD 38.0 million. Third quarter EBITDA
included the recognition of USD 101 million associated with the transfer of
technology to the Yulin JV. The underlying comparable EBITDA decreased by
approximately 17 percent compared to the prior quarter, primarily due to lower
polysilicon prices.
The polysilicon and silane gas loading expansion projects at Moses Lake and
Butte are proceeding according to schedule. Building permits have been obtained
and construction activity has commenced. The Yulin Joint Venture is also
progressing according to plan. The contract on detailed engineering has been
awarded and the work has commenced. REC Silicon made the first capital
contribution of USD 75 million to the JV in October 2014.
"Continued focus on efficient and stable operations resulted in record high
production volumes and secured REC Silicon's competitive cost position.
Although challenging market dynamics and the uncertainty created by the US/China
trade dispute led to pressure on solar grade polysilicon prices during the
quarter, REC Silicon's financials remain strong," commented Tore Torvund, CEO of
REC Silicon.
Net financial items resulted in income of USD 112.8 million, mainly reflecting
net currency gains, and fair value adjustment of convertible bonds offset by
interest expense.
Profit from continuing operations was USD 119.0 million in the fourth quarter,
compared to USD 119.5 million in the previous quarter.
Basic and diluted EPS from total operations was USD 0.05 in the fourth quarter
2014, unchanged from the previous quarter.
For more information, please see the attached fourth quarter 2014 report.
Morning program:
The Company will give a presentation at 08:00 a.m. CET today at
Konferansesenteret Høyres Hus, Stortingsgaten 20, 0117 Oslo, Norway. The
presentation will be held in English.
There will be a live webcast from the presentation which can be accessed from:
www.recsilicon.com.
It will also be possible to listen to the presentation through a conference
call. Please make sure to dial in 10 minutes prior to scheduled start time on
one of the following numbers:
Norway: +47 23 50 04 86
UK: +44 (0)20 3427 1909
USA: +1 212 444 0412
International Toll: +44 (0)20 3427 1909
Please provide confirmation code 7022732 and state your name, company and
country of residence.
Afternoon program:
REC Silicon will host an analyst conference call with possibilities for
questions and answers later the same day at 3:00 p.m. CET. Please make sure to
dial in at least five minutes ahead of time to complete your registration.
International dial in: +47 23 50 04 86
Please provide confirmation code 1521035 and state your name, company and
country of residence.
For further information, please contact:
Mitra H. Negård, Investor Relations
REC Silicon ASA
Phone: +47 957 93 631
Email: mitra.negard@recsilicon.com
About REC Silicon
REC Silicon is a leading producer of advanced silicon materials, delivering
high-purity polysilicon and silicon gas to the solar and electronics industries
worldwide. We combine 25 years of experience and proprietary technology with the
needs of our customers, and annual production capacity of more than 20,000 MT of
polysilicon from our two US-based manufacturing plants. Listed on the Oslo Stock
Exchange (ticker: REC), the company is headquartered in Moses Lake, Washington
and employs 720 people.
For more information: www.recsilicon.com
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
RNWEFY EARNINGS...
Fornebu, February 13, 2015: REC Silicon ASA reported fourth quarter 2014
revenues of USD 126.2 million compared to USD 126.5 million in the third
quarter. Higher polysilicon sales volumes were offset by lower polysilicon
prices and decreased sales volumes of silicon gases.
EBITDA for the fourth quarter was USD 38.0 million. Third quarter EBITDA
included the recognition of USD 101 million associated with the transfer of
technology to the Yulin JV. The underlying comparable EBITDA decreased by
approximately 17 percent compared to the prior quarter, primarily due to lower
polysilicon prices.
The polysilicon and silane gas loading expansion projects at Moses Lake and
Butte are proceeding according to schedule. Building permits have been obtained
and construction activity has commenced. The Yulin Joint Venture is also
progressing according to plan. The contract on detailed engineering has been
awarded and the work has commenced. REC Silicon made the first capital
contribution of USD 75 million to the JV in October 2014.
"Continued focus on efficient and stable operations resulted in record high
production volumes and secured REC Silicon's competitive cost position.
Although challenging market dynamics and the uncertainty created by the US/China
trade dispute led to pressure on solar grade polysilicon prices during the
quarter, REC Silicon's financials remain strong," commented Tore Torvund, CEO of
REC Silicon.
Net financial items resulted in income of USD 112.8 million, mainly reflecting
net currency gains, and fair value adjustment of convertible bonds offset by
interest expense.
Profit from continuing operations was USD 119.0 million in the fourth quarter,
compared to USD 119.5 million in the previous quarter.
Basic and diluted EPS from total operations was USD 0.05 in the fourth quarter
2014, unchanged from the previous quarter.
For more information, please see the attached fourth quarter 2014 report.
Morning program:
The Company will give a presentation at 08:00 a.m. CET today at
Konferansesenteret Høyres Hus, Stortingsgaten 20, 0117 Oslo, Norway. The
presentation will be held in English.
There will be a live webcast from the presentation which can be accessed from:
www.recsilicon.com.
It will also be possible to listen to the presentation through a conference
call. Please make sure to dial in 10 minutes prior to scheduled start time on
one of the following numbers:
Norway: +47 23 50 04 86
UK: +44 (0)20 3427 1909
USA: +1 212 444 0412
International Toll: +44 (0)20 3427 1909
Please provide confirmation code 7022732 and state your name, company and
country of residence.
Afternoon program:
REC Silicon will host an analyst conference call with possibilities for
questions and answers later the same day at 3:00 p.m. CET. Please make sure to
dial in at least five minutes ahead of time to complete your registration.
International dial in: +47 23 50 04 86
Please provide confirmation code 1521035 and state your name, company and
country of residence.
For further information, please contact:
Mitra H. Negård, Investor Relations
REC Silicon ASA
Phone: +47 957 93 631
Email: mitra.negard@recsilicon.com
About REC Silicon
REC Silicon is a leading producer of advanced silicon materials, delivering
high-purity polysilicon and silicon gas to the solar and electronics industries
worldwide. We combine 25 years of experience and proprietary technology with the
needs of our customers, and annual production capacity of more than 20,000 MT of
polysilicon from our two US-based manufacturing plants. Listed on the Oslo Stock
Exchange (ticker: REC), the company is headquartered in Moses Lake, Washington
and employs 720 people.
For more information: www.recsilicon.com
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
SO Sad.. The saga continues and the same continue to defend.. One day,, hopefully soon we will know the truth but for now,, sitting on the sidelines has become has become a sport of wanting reality by some and continued denial by others.. I think we will see a blending of both when the final bell rings and the JAIL TERMS are finally given.. hank
Nice close.. $0.0017.. BTW I will not be posting here for a while because it's all about the numbers anyway.. If and when ACGX stops diluting which will be not some time soon and just one of the promises made during the past year by the company comes true,, quite frankly there is no amount of money or time ACGX can spend to reverse the attitude twards it.. It in reality is a stinky pinkey with an attempt to put lipstick on a PIG but,, any one looking further they will know the real ACGX.. If you haven't heard the broadcast,, I think you should because it was announced that conversions will not stop,, as long as Preferred are sold to friends and family of ACGX.. Wash and Rinse..
Your Answer is right here..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110339107
But how could that be if they are already a distributor..??
I don't know but I've got a copy cat using my 8888's.. I think we are close but I'm also surprised that if we are why the seller hasn't moved up and enjoyed the ride.. Also some of the selling appears to be coming from tired shareholders.. hank
ACGX $0.0014.. Earnings.. It appears that all numbers are W/O taxes.. A FULL SEC FILING IS NEEDED to see what the taxes are and earnings after taxes..
Quarterly Financials for Alliance Creative Group Inc.
All values USD millions.
30-Sep-2013 31-Dec-2013 31-Mar-2014 30-Jun-2014 30-Sep-2014
Sales/Revenue 2.66M 3.27M 3.3M 3.01M 2.81M
Cost of Goods Sold (COGS) incl. D&A 1.97M 2.42M 2.41M 2.26M 2.09M
COGS excluding D&A 1.97M 2.42M 2.41M 2.26M 2.09M
Gross Income 689,488 843,112 890,474 753,317 724,691
SG&A Expense 644,650 634,165 593,077 719,483 687,675
Other SG&A 644,650 634,165 593,077 719,483 687,675
Non Operating Income/Expense 9,225 (591) 29,400 6,332 (23,364)
Pretax Income 54,062 208,356 326,796 40,165 13,651
Consolidated Net Income 54,062 208,356 326,796 40,165 13,651
Net Income 54,062 208,356 326,796 40,165 13,651
Net Income After Extraordinaries 54,062 208,356 326,796 40,165 13,651
Net Income Available to Common 54,062 208,356 326,796 40,165 13,651
EPS (Basic) 0.00 0.00 0.00 0.00 0.00
Basic Shares Outstanding 290.14M 485.52M 566.27M 688.3M 707.16M
EPS (Diluted) 0.00 0.00 0.00 0.00 0.00
Diluted Shares Outstanding 290.14M 485.52M 566.27M 688.3M 707.16M
EBITDA 44,838 - - - 37,016
Check the receivables on the next report and see if they are getting paid.. hank
ACGX..$0.0013 Down 23%..Why is it of any information what ACGX earned last year..???
He also posts he built another company from scratch to over $100,000,000.00.
.Question does anyone know the name of that company and where it is today..??
I do but it came after the Flotation deal and the partner snubbing DEEP DOWN when they sold I realized we were dealing with a group of self dealing novices.. But I also held a sizeable position that OK because of all the hype and over reaching expectation and the reading of the charts action.. But I sold most above $2.20 and held but 25K that went out the door in the $1.80's.. They are the joke of the industry around the Gulf.. hank
Nigeria Delay's Election
Nigeria's February 14th election day is postponed by 6 weeks due to Boka Haram? Or is this an election ploy excuse due to a very tight race?
(Bloomberg) -- Nigeria will delay presidential and legislative elections for six weeks as a multinational force battles Islamic militants in northeastern areas of the country, the Associated Press reported, citing an unidentified official.
Voting wouldn’t be able to go ahead in large parts of the northeast if elections proceeded as scheduled on Feb. 14, AP said, citing the official, who spoke on condition of anonymity. The postponement will be announced by the Independent National Electoral Commission at a press conference later on Saturday, AP reported.
“The commission has not made that call,” Kayode Idowu, an INEC spokesman, said by e-mail today when contacted by Bloomberg. It will hold a press briefing at 5 p.m. in the capital, Abuja, to state whether the vote will go ahead as originally planned, Idowu said.
President Goodluck Jonathan’s ruling People’s Democratic Party will face a united opposition led by former military ruler Muhammadu Buhari in what analysts expect will be the tightest contest since the PDP came to power in 1999.
INEC officials are meeting with political parties to discuss the country’s readiness to hold elections. The commission’s Chairman Attahiru Jega briefed a cabinet meeting on the issue on Thursday.
Nigeria, Africa’s biggest economy and most populous nation, is engaged in a fight with Islamist militants known as Boko Haram. The group has 4,000 to 6,000 fighters and since July it has taken and held about 30 towns and villages in the northeast giving it an operating base, according to two U.S. intelligence officials who spoke on the condition of anonymity.
Read more at http://www.stockhouse.com/companies/bullboard/t.mmt/mart-resources-inc#IZTx3cim7T5Eq2Ft.99
Yes and I heard nothing about share counts ,, purchase prices or anything else that gave a number that was solid for the bottom line and earnings.. They were profitable doesn't cut it with me because all the other companies that went into ACGX or it's former names had great promise and have disappeared with the exception of The Printing Company..
.. The COO posts that ne built a 100 Million dollar company from almost scratch.. Did you ever get it's name and what it's doing now..??
ALSO: From the Info Board..
We have also become a distributor for some child resistant packaging and are in discussions with other
packaging companies in the cannabis industry to expand our products and services... This seem far from the ans. that he gave in the interview.. One implys actual sales and distribution moving forward while the latest doesn't..
This was to have a patent.. Did they ever give a patent or patent pending number.. "Still in the works".. Was that a PR statement or are there any facts..???
Did he mention how and how much they paid for it and what it will bring to the bottom line.. Also will it have any effect on EPS.. Real Investors need the Answers to basic questions.. Not just that is a good deal.. What actually will it do for the bottom line and what and how they paid for it please..
Any Ides when the Auth, Shares Outstanding will be changed upwards..??
Since they have never had the below when do you expect the following,, unless you consider the K's but they have never detailed the cost of acquiring or disposing of any thing in the past....??
"More info on that expected in future disclosure statements"
DGPIF.. $0.615 USD.. Trading crazy in Canada..
How many of the questions below were answered by the Paid for ($10,000.00) radio Interview..?? I see the sellers are lined up with their many millions hoping that some one buy's something.. Total Volume (1.28:)today.. 35,617 Shares
ACGX = Key Questions that Need Answered!
1. Why does the company insist on continual dilution of shareholders for the debt of past failures and not financing thru a bank credit that has been touted as evidence of their unaudited financials. 750,000,000 shares have come to the open market in less than. 1 1/2 years. The company has talked about revenue growth as being the focus of success, whereas shareholders own less and less of the company.
2. If the officers of this company think their stock is that undervalued and frustrated alongside of all of us, why are the officers not buying shares like the rest of us shareholders that they are promoting as undervalued?
3. Why does the company seem to go into hybernation with investor relations and not after many years of complaints have a consistent stream of communication thru pr campaigns or shareholder updates that cost nothing for website updates?
4. PeopleVine has been touted as a huge deal that the company has incorporated. In the past 5 years there have been also deals acquired like in STLK and Imageworld wide. How do all these different entities add value to the company shareholders.what is the real focus of ACG going forward, what is the main goals? Debt?
5. Recently the COO requested a response to questions about the option of increasing a/s verses a reverse split. We all know that a reverse split is death to shareholders and the conference call alluded to this mistake in April 2014. Why would this question even be a consideration? It brings distrust to the officers for that was a withdrawn conclusion a year ago.
6. In the stock radio interview in June 2014 Cannabis was touted as a huge interest and brought many marijuana investors into this stock at much higher prices than .001s today. Why has this patent and cannabis initiative not been expressed more frequently other than mentions in the filing. This is a huge movement and emphasised as a initiative with what seems to be NO follow thru. Why?
7. The company touts not to be a pump and dump stock, but the stock has gone down 8 straight months and lacks shareholder updates. What efforts are being made to boost confidence that shareholders are going to receive more consistent updates on what this company is doing in day to day operations. Why isnt the story being told?
8. Audting the financials seems to be an ongoing question. A profitable company trading @ less than a 1/5th of a penny makes everyone wonder whats really under the hood. Even before the last reverse split IVIT talked about 10M in revenues and being profitable. How is ACGX any different than IViT and how as shareholders can we be confident this managment team isnt going to turn around from what they say and screw us all into another IVIT like reverse split where prefeered shares are not affected. Altogether many seem to be hesitant to believe the story here for reasons just mentioned.